Notable Movers: RadioShack Corporation (NYSE:RSH), Cell Therapeutics Inc (NASDAQ:CTIC), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Lakeway, NY -- (SBWIRE) -- 02/25/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

RadioShack Corporation (NYSE:RSH) shares dropped 3.16% and closed at $3.06 in the last trading session. The company will host a live webcast of its fourth-quarter earnings conference call with investors starting at 9 a.m. ET on Tuesday, Feb. 26, 2013, to review financial results for the fourth quarter, which ended December 31, 2012.

Additionally, RSH‘s stock had its “underperform” rating restated by analysts at Wedbush in a research report issued to clients and investors on Feb. 21. They currently have a $1.00 price target on the stock. Separately, analysts at Barclays Capital reiterated an “equal weight” rating on shares of RadioShack in a research note to investors on February 13. They now have a $2.00 price target on the stock.

How Should Investors Trade RSH After The Recent Price movement? Find out Here

Cell Therapeutics Inc (NASDAQ:CTIC) shares declined 2.90% to $1.34 in the previous trading session. The company, on Jan. 31, announced that the Gynecologic Oncology Group (GOG) informed CTIC that an independent Data Safety Monitoring Board (DSMB) recommended continuation of the GOG-0212 Phase 3 clinical trial of OPAXIOTM (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis.

CTIC remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled approximately 1,000 of the planned 1,100 patients. Enrollment is expected to be completed in 2013.

Is CTIC a Strong Buying Opportunity After The Recent Slump? Find out Here

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares jumped 1.66% and closed at $6.13. Cowen initiated coverage on shares of ACADIA in a research note released on Jan. 28. The firm issued an outperform rating on the stock.

Additionally, the company, last month, announced the election of Stephen R. Biggar, M.D., Ph.D., to its board of directors. Dr. Biggar will fill a vacancy on ACADIA’s board and serve as a Class II director. The terms of the Class II directors will expire at the annual meeting of stockholders in 2015.

Is ACAD a Buy After The Latest Price Action? Find Out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.